STEK · Stemtech Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03M | $697.9K | $868.0K | - | $1.33M | $1.38M | - | $1.30M | $1.13M | $1.13M |
| Cost of Revenue | $380.2K | $145.9K | $345.4K | - | $246.2K | $345.4K | - | $290.9K | $246.2K | $244.8K |
| Gross Profit | $651.4K | $552.0K | $720.3K | - | $993.6K | $1.04M | - | $1.01M | $881.9K | $888.5K |
| R&D | $0 | $0 | $0 | - | $0 | $0 | - | $0 | $177 | $0 |
| SG&A | $1.18M | $698.0K | $1.73M | - | $1.34M | $1.62M | - | $1.08M | $1.60M | $1.68M |
| Total Operating Expenses | $1.37M | $853.0K | $1.93M | - | $1.69M | $2.05M | - | $1.59M | $1.85M | $2.14M |
| D&A | - | - | $41.9K | - | - | $154.1K | - | - | - | $119.6K |
| Operating Income | ($716.5K) | ($301.0K) | ($1.20M) | - | ($692.3K) | ($1.01M) | - | ($579.0K) | ($967.6K) | ($1.25M) |
| Interest Expense | $493.5K | $79.7K | $245.4K | - | $117.4K | $431.0K | - | - | - | - |
| Income Tax | $0 | $0 | $0 | - | $0 | $0 | - | $33.5K | $0 | ($35.4K) |
| Net Income | ($1.17M) | ($293.1K) | ($1.46M) | - | ($784.2K) | ($1.42M) | - | ($1.04M) | ($286.9K) | ($2.24M) |
| EPS - Basic | ($0.01) | $0.00 | ($0.01) | - | ($0.01) | ($0.02) | - | ($0.01) | $0.00 | ($0.04) |
| EPS - Diluted | ($0.01) | $0.00 | ($0.01) | - | ($0.01) | ($0.02) | - | ($0.01) | $0.00 | ($0.04) |
Balance Sheet
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $259.6K | $272.4K | $305.8K | $255.3K | $259.6K | $274.0K | $114.2K | $323.6K | $283.9K | $343.3K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $234.6K | $274.8K | $188.4K | $197.4K | $57.4K | $57.5K | $48.3K | $84.1K | $225.7K | $109.1K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $1.02M | $1.10M | $936.1K | $921.7K | $617.9K | $511.1K | $400.7K | $694.7K | $764.0K | $750.8K |
| Total Assets | $3.76M | $3.87M | $3.75M | $3.78M | $3.69M | $3.61M | $3.68M | $4.15M | $4.40M | $4.56M |
| Current Liabilities | $10.30M | $10.32M | $9.44M | $9.01M | $8.62M | $8.06M | $6.46M | $5.85M | $5.71M | $9.26M |
| Long-term Debt | $4.12M | $4.14M | $4.16M | $3.82M | $3.73M | $3.73M | $3.49M | $2.75M | $2.41M | - |
| Total Liabilities | $10.30M | $10.32M | $9.44M | $9.01M | $8.62M | $8.06M | $6.46M | $5.85M | $5.71M | $9.27M |
| Stockholders' Equity | ($5.80M) | ($5.71M) | ($4.94M) | ($4.48M) | ($4.19M) | ($3.70M) | ($2.04M) | ($956.8K) | ($568.0K) | ($3.98M) |
| Retained Earnings | ($33.40M) | ($32.58M) | ($32.29M) | ($30.83M) | ($29.26M) | ($28.48M) | ($27.06M) | ($25.20M) | ($24.15M) | ($23.87M) |
Cash Flow
| Line item | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($710.5K) | - | - | $1.02M | - | - | - | ($574.7K) |
| Investing Cash Flow | - | - | $0 | - | - | $0 | - | - | - | $0 |
| Financing Cash Flow | - | - | $78.8K | - | - | $51.7K | - | - | - | $798.6K |
| CapEx | - | - | $0 | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | ($710.5K) | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 63.1% | 79.1% | 83.0% | - | 74.9% | 75.0% | - | 77.6% | 78.2% | 78.4% |
| Operating margin | -69.5% | -43.1% | -138.8% | - | -52.2% | -73.1% | - | -44.6% | -85.8% | -110.4% |
| EBITDA margin | - | - | -134.0% | - | - | -62.0% | - | - | - | -99.8% |
| Net margin | -113.5% | -42.0% | -167.7% | - | -59.1% | -102.6% | - | -80.2% | -25.4% | -197.4% |
| Free cash flow margin | - | - | -81.9% | - | - | - | - | - | - | - |
| FCF / Net income | - | - | 0.49 | - | - | - | - | - | - | - |
| R&D / Revenue | 0.0% | 0.0% | 0.0% | - | 0.0% | 0.0% | - | 0.0% | 0.0% | 0.0% |
| SG&A / Revenue | 114.3% | 100.0% | 199.0% | - | 101.4% | 117.1% | - | 83.3% | 141.9% | 148.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -31.2% | -7.6% | -38.8% | - | -21.2% | -39.3% | - | -25.1% | -6.5% | -49.1% |
| Return on equity | 20.2% | 5.1% | 29.5% | - | 18.7% | 38.3% | - | 108.9% | 50.5% | 56.3% |
| Return on invested capital | - | - | - | - | - | -3710.7% | - | -25.5% | -41.5% | - |
| Liquidity | ||||||||||
| Current ratio | 0.10 | 0.11 | 0.10 | 0.10 | 0.07 | 0.06 | 0.06 | 0.12 | 0.13 | 0.08 |
| Quick ratio | 0.08 | 0.08 | 0.08 | 0.08 | 0.07 | 0.06 | 0.05 | 0.10 | 0.09 | 0.07 |
| Cash ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | 0.06 | 0.05 | 0.04 |
| Leverage | ||||||||||
| Debt / Equity | -0.71 | -0.73 | -0.84 | -0.85 | -0.89 | -1.01 | -1.71 | -2.88 | -4.24 | - |
| Debt / Assets | 1.10 | 1.07 | 1.11 | 1.01 | 1.01 | 1.03 | 0.95 | 0.66 | 0.55 | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -1.5x | -3.8x | -4.9x | - | -5.9x | -2.3x | - | - | - | - |
| Equity multiplier | -0.65 | -0.68 | -0.76 | -0.84 | -0.88 | -0.98 | -1.81 | -4.34 | -7.75 | -1.15 |
| Liabilities / Assets | 2.74 | 2.67 | 2.51 | 2.38 | 2.34 | 2.23 | 1.75 | 1.41 | 1.30 | 2.03 |
| Efficiency | ||||||||||
| Asset turnover | 0.27 | 0.18 | 0.23 | - | 0.36 | 0.38 | - | 0.31 | 0.26 | 0.25 |
| Inventory turnover | 1.62 | 0.53 | 1.83 | - | 4.29 | 6.01 | - | 3.46 | 1.09 | 2.24 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 225d | 687d | 199d | - | 85d | 61d | - | 105d | 335d | 163d |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | 1.5x | 5.5x | 4.5x | - | 5.1x | 4.7x | - | 2.9x | 5.1x | 5.3x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -47.4% | -37.2% | - | 17.5% | 22.0% | - | 24.0% | 10.0% | 5.4% |
| Revenue CAGR (3y) | -0.5% | -12.0% | -6.9% | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -44.4% | -30.6% | - | 12.7% | 16.7% | - | 16.3% | 16.7% | -0.8% |
| Operating income growth (YoY) | - | 56.5% | -19.2% | - | 28.5% | 19.2% | - | 82.9% | -67.3% | -1566.1% |
| Net income growth (YoY) | - | 62.6% | -2.6% | - | -173.3% | 36.6% | - | - | 62.4% | -352.1% |
| EPS growth (YoY) | - | - | 50.0% | - | - | 50.0% | - | - | - | -300.0% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -36.3% | -33.3% | -119.9% | -637.1% | 6.8% | 16.2% | 76.1% | 98.0% | -0.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$2.88M totalLatin America$1.53M · 53.2%
Americas$1.23M · 42.8%
Asia$116.9K · 4.1%
Peer comparison
Same SIC group: Wholesale-Drugs, Proprietaries & Druggists' Sundries
Comparing Stemtech Corp against the 5 most active filers in the same SIC group.